Transgene S.A.
PAR: TNG.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alessandro Riva
- Employees
- 144
- Headquarters
- Illkirch-Graffenstaden, France
- IPO year
- 2000
- Market cap
- €112.5M
- Website
- https://www.transgene.fr
Loading TNG…
Loading profile data…Frequently asked questions about TNG
What does Transgene S.A. (TNG.PA) do?
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head...
Where does TNG.PA trade?
Transgene S.A. (TNG.PA) trades on the Euronext Paris.
What sector is TNG.PA in?
Transgene S.A. (TNG.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Transgene S.A.?
Alessandro Riva is the chief executive officer of Transgene S.A. (TNG.PA).
Where is Transgene S.A. headquartered?
Transgene S.A. is headquartered in France.
Does TNG.PA pay a dividend?
Transgene S.A. (TNG.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TNG.PA go public?
Transgene S.A. (TNG.PA) completed its initial public offering in 2000.